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Abstract
Context: Expression and activity of the main lipogenic enzymes is paradoxically decreased in obesity, but the mechanisms
behind these findings are poorly known. Breast Cancer 1 (BrCa1) interacts with acetyl-CoA carboxylase (ACC) reducing the
rate of fatty acid biosynthesis. In this study, we aimed to evaluate BrCa1 in human adipose tissue according to obesity and
insulin resistance, and in vitro cultured adipocytes.
Research Design and Methods: BrCa1 gene expression, total and phosphorylated (P-) BrCa1, and ACC were analyzed in
adipose tissue samples obtained from a total sample of 133 subjects. BrCa1 expression was also evaluated during in vitro
differentiation of human adipocytes and 3T3-L1 cells.
Results: BrCa1 gene expression was significantly up-regulated in both omental (OM; 1.36-fold, p = 0.002) and subcutaneous
(SC; 1.49-fold, p = 0.001) adipose tissue from obese subjects. In parallel with increased BrCa1 mRNA, P-ACC was also up-
regulated in SC (p = 0.007) as well as in OM (p = 0.010) fat from obese subjects. Consistent with its role limiting fatty acid
biosynthesis, both BrCa1 mRNA (3.5-fold, p,0.0001) and protein (1.2-fold, p = 0.001) were increased in pre-adipocytes, and
decreased during in vitro adipogenesis, while P-ACC decreased during differentiation of human adipocytes (p = 0.005)
allowing lipid biosynthesis. Interestingly, BrCa1 gene expression in mature adipocytes was restored by inflammatory stimuli
(macrophage conditioned medium), whereas lipogenic genes significantly decreased.
Conclusions: The specular findings of BrCa1 and lipogenic enzymes in adipose tissue and adipocytes reported here suggest
that BrCa1 might help to control fatty acid biosynthesis in adipocytes and adipose tissue from obese subjects.
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Introduction
The complex process of differentiation by which new fat cells
are developed from pre-adipocytes is known as adipogenesis.
During this process, the most dramatic changes are observed in
relation to structural changes that allow the biosynthesis of lipids
(or lipogenesis). Fatty acid synthase (FASN; EC 2.3.1.85) and
acetyl-CoA carboxylase (ACC; EC 6.4.1.2) are examples of master
enzymes in lipogenesis [1,2]. The later, ACC, catalyses the
formation of malonyl-CoA, an essential substrate for FASN and
the chain elongation systems [2,3]. ACC is present in the cytosol of
all tissues and is especially enriched in adipose tissue and liver. The
acute control of ACC activity is the product of integrated changes
such as the phosphorylation of multiple serine residues and
interactions with other proteins [see [3] for references].
The expression of lipogenic enzymes is decreased in overweight
and obese subjects [4,5,6,7,8]. However, the hyperplasic compo-
nent of adipose tissue is currently well recognized and refers both
to the recruitment and proliferation of adipocyte precursor cells
(also named pre-adipocytes) [9,10,11] followed by adipogenesis
[12,13]. Since the development of obesity involves an extensive
adipose tissue remodeling which is dependent on the coordinated
interplay between adipocyte hypertrophy (increase in cell size
assessed during adipogenesis) and adipocyte hyperplasia (increase
in cell number) [14,15], the before mentioned findings seem to be
contrary to what might be expected.
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Otherwise, it is well known that chronic subclinical inflamma-
tion is intrinsic to the metabolic syndrome (the clustering of central
obesity and alterations of glucose and lipid metabolism). Insulin
resistance is central to the pathophysiology of these alterations,
which runs together with the accumulation of fat and the presence
of specific components that might be of importance in the
development of type 2 diabetes (T2D) [16]. In this respect, the
transcription factor sterol regulatory element binding protein
(SREBP)-1c transduces the insulin signal in insulin sensitive tissues
such as adipose tissue, and its involvement in lipogenic genes
which require for their expression both insulin and glucose
(namely FAS and ACC) is currently well recognized [17].
Breast Cancer 1 (BrCa1) is a ,220-KDa protein involved in
multiple cellular functions such as DNA repair, cell cycle
checkpoint control, transcription, and ubiquitination [18,19].
BrCa1 mRNA is primarily expressed in a large variety of epithelia
in tissues derived from the ectoderm, endoderm, and mesoderm
[20]. Widespread tissue- and cell-specific expression of the BrCa1
transcript in mammalians has been reported [21,22]. Although
BrCa1 has been shown to have tumor-suppressive properties in
breast and ovarian cells, its broad distribution and its crucial role
in the development of different germ layers during embryogenesis
[23,24,25] suggest a more generalized role that includes both
differentiation [21,22] and cell proliferation [23,24]. This data
suggest an important developmental role for BrCa1 in the
regulation of proliferation and differentiation of many cell lines,
but nowadays little is known about BrCa1 function and the
regulation of its expression in human fat depots, pre-adipocytes
and mature adipocytes.
Recent studies have provided structural evidence for direct
interactions between the BrCa1 C-Terminal (BRCT) domains and
a phospho-peptide from the cytosolic enzyme ACC [26]. It has
been suggested that BrCa1 helps to maintain fatty acid biosyn-
thesis and lipogenesis under control in normal cells, whereas
mutations in the BRCT domains of BrCa1 can abolish the
regulation of ACC and lead to elevated lipogenesis, which is an
important requirement for cancer cell growth [27,28]. Otherwise,
when BrCa1 interacts with ACC preventing ACC dephosphory-
lation, the rate of fatty acid biosynthesis seems to be significantly
reduced [29,30,31]. Therefore, if BrCa1 helps to control fatty acid
biosynthesis in normal cells, it is important to understand this
regulation in the tissue where the most dramatic changes in lipid
biosynthesis take place (i.e. adipose tissue) in association with the
presence of obesity and alterations of glucose and lipid metabo-
lism. Of note, insulin resistance was recently associated with an
expanded population of small adipocytes, suggesting impairment
in adipose cell differentiation in obese subjects with impaired
glucose tolerance [32]. On the other hand, obese individuals often
have enlarged adipocytes with a reduced buffering capacity for
lipid storage leading to ectopic fat deposition and insulin resistance
[33].
Interestingly, BrCa1 was found to be up-regulated in adipose
tissue from obese subjects independently of T2D. To gain further
insight into the meaning of this finding, we also analyzed BrCa1
mRNA during in vitro differentiation of human pre-adipocytes, in
mature adipocytes treated with inflammatory stimuli (macrophage
conditioned medium), and both BrCa1 and phosphorylated-
BrCa1 protein in 3T3-L1, in parallel to phosphorylation of ACC.
Results
BrCa1 levels in human fat samples
The anthropometric and metabolic characteristics of the study
subjects are shown in Table 1. Obese subjects with type 2 diabetes
(T2D) were identified from obese outpatient clinics on the basis of
a stable metabolic control in the previous 6 months, as defined by
stable HbA1c and fasting glucose values. BrCa1 gene expression
levels in both subcutaneous (1.46-fold, p = 0.005; Fig. 1a) and
omental (1.36-fold, p = 0.002; Fig. 1c) fat depots, as well as total
(Fig. 1e) and phosphorylated (Fig. 1f) BrCa1 protein (1.35-fold,
p = 0.007, and 1.50-fold, p = 0.016, respectively), were significantly
increased in obese when compared to non-obese subjects.
Concomitantly, SREBP-1c, FASN and ACC gene expression levels
were down-regulated in adipose tissue from obese subjects
(Table 1). BrCa1 expression was significantly increased by 1.34-
fold (p = 0.001) in SC versus OM adipose tissue (n = 51-paired
samples; Figure S1a). Gene expression measures for BrCa1 in
OM and SC fat were significantly associated (r = 0.37, p = 0.004).
Consistent with increased BrCa1 in obesity, increased P-ACC
levels were shown in both SC (1.9-fold, p= 0.007; Fig. 1b) and
OM (2.1-fold, p = 0.010; Fig. 1d) adipose tissue from obese
subjects (Table 1), and in SC when compared to OM fat depots
(1.7-fold, p = 0.001; Fig. S1b). As expected, both ACC gene
expression and protein levels, and FASN gene expression were
decreased in obese subjects when compared to non-obese
individuals (Table 1). Also SREBP-1c gene expression was lower
in SC and OM fat from obese subjects with or without T2D
(Table 1).
In the whole cohort, BrCa1 mRNA in SC fat was significantly
associated with BMI (r = 0.265, p = 0.009), fasting glucose
(r = 0.256, p = 0.011), and LDL-cholesterol (r = 0.300, p = 0.008),
while OM BrCa1 gene expression was also associated with BMI
(r = 0.343, p = 0.001) and fasting glucose (r = 0.389, p,0.0001),
fasting insulin (r = 0.310, p = 0.011), HOMA-IR (r = 0.335,
p = 0.007), and LDL-cholesterol (r = 0.300, p= 0.008). Interest-
ingly, fasting glucose contributed independently to 19.6%
(p= 0.02) of OM and 15.1% (p= 0.05) of SC BrCa1 gene
expression variance after controlling for the effects of sex, age,
and BMI in a multiple linear regression model.
On the other hand, BrCa1 gene expression in isolated human
adipocytes was increased 1.7-fold (p,0.0001; Fig. S2) in mature
adipocytes isolated from both SC (n= 12) and OM (n= 12)
adipose tissue samples when compared with stromal-vascular cells
(SVCs). The higher BrCa1 gene expression in isolated mature
adipocytes was in parallel to the increased FASN (,39-fold,
p,0.0001), ACC (,7-fold, p,0.0001), and SREBP (,5-fold,
p,0.0001) gene expression levels (Figure S2).
BrCa1 in cultured adipocytes
BrCa1 gene expression decreased during in vitro differentiation of
human pre-adipocytes (277.4%, p,0.0001, at day 7, and
266.2%, p,0.0001, at day 14; Fig. 2a) in parallel to increased
expression levels of SREBP1 (,5-fold, p= 0.03), FASN (,57-fold,
p = 0.04; Fig. 2b), and ACC (,3-fold, p = 0.005; Fig. 2c), and
decreased P-ACC/ACC ratio (2.1-fold, p = 0.005; Fig. 2d).
The finding of decreased BrCa1 expression in mature adipocytes
vs pre-adipocytes was in contrast with the results for comparisons
between mature adipocytes and SVCs isolated from adipose tissue
of obese individuals. Thereby we sought to evaluate the
immunomodulating effects of inflammatory stimulus such as the
macrophage conditioned medium (MCM; 25%) on mature
adipocytes. Macrophages have been showed to be at the onset
of metabolic diseases by triggering sustained inflammation [34].
THP-1 cells stimulated with lipopolysaccharides (LPS) released to
the media high levels of pro-inflammatory cytokines such as IL-8,
monocyte chemotactic protein-1, IL-6, and tumor necrosis factor-
a, among others [35]. Being this model suitable to study the first
potential events leading to the impairment of mature adipocytes
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behavior, our data suggest that the expression of BrCa1 could be at
the onset of decreased lipogenesis in human adipocytes under
inflammatory conditions.
Interestingly, macrophage conditioned medium (MCM; 25%)
restored BrCa1 gene expression in mature adipocytes to the levels
assessed for pre-adipocytes (+270%, p,0.0001), whereas ACC
(278%, p,0.0001) and FASN (282%, p= 0.009) gene expression
was significantly down-regulated (Fig. 2). To further substantiate
these findings, we confirmed decreased BrCa1 protein (220.7%,
p= 0.010, at day 7, and 218.9%, p= 0.017, at day 14) during
differentiation of 3T3-L1 cells (Fig. 2e).
Discussion
Decreased lipogenesis in obese subjects, characterized and
defined by increased body fatness, is repeatedly found in the
literature (summarized in reference [6]). No consistent mechanistic
insights have been reported to explain this contradictory
observation. In this respect, sterol regulatory element-binding
protein (SREBP)-1c is a well established key transcription factor
for the regulation of lipogenic enzymes in hepatocytes but the
mechanisms of lipogenic genes regulation in adipocytes remains
unclear. Of note, the genetic disruption of SREBP-1 did not cause
changes in lipogenic gene expression in adipose tissue [36], and
increments in SREBP-1c are not accompanied by transactivation
of lipogenic genes in adipocytes, unlike in hepatocytes [37].
In the current study, we evaluated BrCa1 gene expression and
protein levels in human adipose tissue, and in human and murine
adipocytes. The principal findings were i) the increased expression
levels of BrCa1 in both omental (OM) and subcutaneous (SC) fat
depots from obese subjects; ii) the higher expression found in SC
when compared to OM fat, iii) the increased expression of BrCa1
mRNA in mature adipocytes when compared with stromal-
vascular cells (SVCs), and iv) the down-regulation of BrCa1 gene
expression and protein during differentiation of both human and
murine adipocytes, which can be restored by inflammatory stimuli
(i.e. the macrophage LPS-conditioned medium). It can be
concluded that the findings of increased BrCa1 in adipose tissue
and during adipogenesis were specular to those of lipogenic
enzymes such as ACC and FASN.
Although its biological function is not completely understood,
BrCa1 seems to have an important role in both cellular
differentiation and proliferation [22,24]. Recent studies have
provided structural evidence for direct interactions between BrCa1
and ACC [26]. BrCa1 helps to control fatty acid biosynthesis and
lipogenesis in normal cells [27,29]. Other studies have demon-
strated that BrCa1 affects lipid synthesis by preventing ACC
dephosphorylation [30]. Our findings are the first to suggest, to
Figure 1. BrCa1 levels in human fat samples. Real Time-PCR: Mean and 95% confidence interval for the mean of gene expression levels for BrCa1
in subcutaneous (SC; Fig. 1a) and omental (OM; Fig. 1c) adipose tissue from non-obese (BMI,30 kg/m2) and obese (BMI$30 kg/m2) subjects with and
without T2D. ELISA: Mean 62.0 SE for phosphorylated ACC normalized versus total ACC (ratio P-ACC/ACC) in SC (Fig. 1b; n = 33) and OM (Fig. 2d;
n = 21) adipose tissue. Western-blot: Mean 62.0 SE of total (BrCa1, Fig. 2e) and phosphorylated (P-BrCa1; Fig. 2f) BrCa1 protein normalized versus b-
actin in OM fat. { and * p,0.05 for comparisons between obese with and without T2D, and the control group (non-obese and non-T2D individuals),
respectively. # p,0.05 for comparisons between non-obese and obese subjects.
doi:10.1371/journal.pone.0033233.g001
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Table 1. Anthropometrical and biochemical characteristics of study subjects.
Whole cohort A. Non-Obese B. Obese C. Obese and T2D P (ANOVA) P (t-Student)
n (SC) 18 59 19
Sex (% women) 67 61 68
Age (years) 46610 43610 47612 0.251 0.337
BMI (kg/m2) 26.5±2.3 43.6±7.0 45.4±7.8 ,0.0001 ,0.0001
Fasting glucose (mg/dL) 85.9±10.6 95.2±14.1 116.5±17.0 ,0.0001 ,0.0001
Fasting insulin (mUI/mL){ 6.7±1.4 13.5±7.9 22.1±19.3 0.032 0.112
HOMA-IR{ 1.42±0.23 3.46±2.46 6.45±5.64 0.024 0.142
HbA1c (%) 4.9±0.6 4.9±0.5 5.1±0.4 ,0.0001 0.622
SC BrCa1 (mRNA) 7.0±3.1 10.2±6.2 11.4±7.4 0.072 0.001
SC FASN (mRNA) 11.4±14.9 3.6±5.3 6.1±4.8 0.026 0.175
SC ACC (mRNA) 4.3±4.4 2.5±2.3 1.5±1.1 0.031 0.088
SC SREBP-1c (mRNA) 1.9±2.1 1.1±0.6 1.0±0.4 0.033 0.084
n (OM) 38 38 12
Sex (% women) 65 53 58
Age (years) 47614 43611 47610 0.301 0.249
BMI (kg/m2) 23.19±2.53 44.18±7.73 45.17±7.79 ,0.0001 ,0.0001
Fasting glucose (mg/dL) 79.74±8.08 94.71±12.94 114.58±20.82 ,0.0001 ,0.0001
Fasting insulin (mUI/mL){ 9.79±5.78 13.87±8.8 41.04±48.2 ,0.0001 0.029
HOMA-IR{ 1.92±0.96 3.57±2.69 11.96±13.63 ,0.0001 0.012
HbA1c (%) 5.02±0.36 4.91±0.48 5.28±0.29 0.002 0.002
OM BrCa1 (mRNA) 6.5±2.5 8.8±4.4 9.0±5.0 0.017 0.002
OM FASN (mRNA) 3.1±1.5 1.9±1.4 1.7±1.3 0.001 ,0.0001
OM ACC (mRNA) 3.8±3.3 2.0±1.1 2.3±1.2 0.008 0.005
OM SREBP-1c (mRNA) 2.1±0.9 1.7±0.8 1.6±0.8 0.058 0.022
Subpopulation of
33 subjects A. Non-Obese B. Obese C. Obese and T2D P (ANOVA) P (t-Student)
n (all women) 6 13 14
Age (years) 3968 41610 4769 0.170 0.209
BMI (kg/m2) 25.8±3.4 44.1±4.3 43.3±3.1 ,0.0001 ,0.0001
Fasting glucose (mg/dL) 84.7±6.6 87.2±12.1 170.4±68.8 ,0.0001 0.001
SC ACC (ng/mg fat) 144.8±119.4 19.8±12.6 17.2±12.0 ,0.0001 0.125
OM ACC (ng/mg fat) 101.66100.4 41.6634.6 35.4628.6 0.100 0.297
Ratio SC P-ACC/ACC 0.40±0.16 0.69±0.19 0.80±0.26 0.014 0.007
Ratio OM P-ACC/ACC 0.23±0.13 0.50±0.22 0.47±0.10 0.037 0.010
Subpopulation of
11 subjects A. Non-Obese B. Obese P (t-Student)
n (all women) 5 6
Age (years) 4269 4765 0.227
BMI (kg/m2) 26.9±4.2 43.6±4.1 ,0.0001
Fasting glucose (mg/dL) 92.8619.0 87.7613.0 0.608
OM BrCa1 (protein) 2.98±0.46 4.02±0.52 0.007
OM P-BrCa1 (protein) 3.27±0.55 4.89±1.11 0.016
OM Ratio P-BrCa1/BrCa1 1.1160.19 1.2260.28 0.457
Data are means 6SD for Non-Obese (BMI,30 Kg/m2), and Obese (BMI$30 Kg/m2) subjects with and without type 2 diabetes (T2D). BMI, Body Mass Index; HbA1c,
glycated hemoglobin; OM, omental fat depots; SC, subcutaneous fat depots; BrCa1, breast cancer protein 1; P-BrCa1, phosphorylated BrCa1; SREBP-1c, sterol
regulatory element-binding protein-1c; FASN, fatty acid synthase; ACC, acetyl-CoA carboxylase; P-ACC, phosphorylated ACC.
{Measures of fasting insulin, and the homeostatic model assessment-insulin resistance (HOMA-IR) were available in 62 individuals (64.5% of the whole cohort). t-
Student was performed for comparisons between non-obese subjects, and merged values from obese subjects with and without T2D. Significant data are shown in
bold.
doi:10.1371/journal.pone.0033233.t001
BrCa1, Lipo/adipogenesis and Adiposity
PLoS ONE | www.plosone.org 4 May 2012 | Volume 7 | Issue 5 | e33233
our knowledge, a close crosstalk between BrCa1, lipogenesis,
adipogenesis, obesity, and obesity-associated insulin resistance.
In the past, variations of BrCa1 expression were observed during
postnatal mammary gland development [21,38] and Cre-mediated
invalidation of this gene affected final differentiation of the gland
during gestation [39]. In humans, the up-regulation of BrCa1 gene
expression observed during the first stages of the mammary gland
also suggested a role for BrCa1 in the differentiation of the
mammary gland [39].
Taking together previous studies and current findings, we
propose that long-lasting fat excess tends to reduce lipogenesis in
adipose tissue as a process aimed at limiting further expansion of
fat mass. Thereby, increased BrCa1 expression in obesity could be
interpreted, as well as the reduced expression for many lipogenic
factors [4,6], as the process through which cells reduce their ability
to synthesize additional fatty acids once the storage capacity limit
of the adipocytes is attained. The decreased activity of ACC in
obesity may be accomplished by increased BrCa1 levels.
Accordingly, the phosphorylation degree for ACC was increased
in adipose tissue from obese subjects when compared to non-obese
individuals, as well as in SC regarding to OM fat depots, and in
pre-adipocytes when compared to mature adipocytes. Therefore,
decreased capacity for fatty acid biosynthesis in pre-adipocytes and
in adipose tissue from obese subjects is confirmed not only through
decreased expression of lipogenic enzymes but also by reducing
their respective specific activities, as previously suggested [40].
We also sought to assess the impact of adipogenesis on BrCa1
expression. The expression of FASN and ACC, two well-
established adipogenic markers, increased, as expected, during
differentiation of pre-adipocytes. Simultaneously, down-regulation
of both BrCa1 gene expression and protein levels (in human
adipocytes and 3T3-L1 cells) was observed. Since BrCa1 is able to
diminish lipogenic activity by interacting with ACC, its down-
regulation at the early stages of differentiation and later in mature
adipocytes could be necessary in order to enable adipogenesis of
human pre-adipocytes.
BrCa1 gene expression levels were significantly increased in
mature adipocytes when compared with SVCs. This again
suggests some kind of regulation in adipose tissue from obese
subjects with a large and long-lasting fat excess. The increase in
BrCa1 gene expression in mature adipocytes might counteract
endogenous lipid synthesis through maintaining ACC phosphor-
ylation and its subsequent inactivation [29]. The decreased
expression of lipogenic enzymes and lipid biosynthesis in adipose
tissue from obese subjects consistently found in the literature
[4,5,6,8] agrees with this observation.
Adipose tissue is important for the production and storage of
cholesterol, as reviewed by Miettinen and Tilvis [41]. Moreover, a
low capacity of large adipocytes to fill up with more lipids could
Figure 2. BrCa1 in cultured adipocytes. Real Time-PCR: Mean62.0 SE of gene expression levels for BrCa1 (Fig. 2a), ACC (Fig. 2b), and FASN (Fig. 2c)
during adipogenesis of human fat cells at days 0, 7th and 14th (n = 3/day) after inducing differentiation, and in mature adipocytes after 48 h treatment
of macrophage conditioned medium (+MCM; 25%). ELISA: Mean62.0 SE for phosphorylated ACC normalized versus ACC total (ratio P-ACC/ACC) after
in vitro differentiation (Fig. 2d) of human pre-adipocytes to mature adipocytes (n = 3/day). Western-blot: Mean 62.0 SE of protein levels for BrCa1
during differentiation of 3T3-L1 (Fig. 2e; n = 4/day). * p,0.0001 and # p,0.05 for comparisons between levels assessed in adipocytes at 7th and/or
14th day after inducing differentiation in vitro, and pre-adipocytes.
doi:10.1371/journal.pone.0033233.g002
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play a role in dyslipidaemia [42]. It is possible that increased fat
cell size in obesity has an impact on lipid metabolism, reducing
fatty acid biosynthesis but also decreasing the uptake of circulating
lipids leading to increased LDL-cholesterol.
On the other hand, inflammation requires the activation of
cellular pathways that reduce deleterious effects in cells. Currently,
emerging evidence has indicated that BrCa1 is involved in ROS
production and oxidative stress responses [43], which can explain
the increased BrCa1 expression in fat samples from obese subjects.
Of note, if the effects of an inflammatory scenario raise BrCa1
expression in mature adipocytes from obese subjects, is it possible
that inflammatory insults can alter the metabolic phenotype of
these cells in vitro, as previously demonstrated [35], and also BrCa1
gene expression. Accordingly, we found an increased expression of
BrCa1 in mature adipocytes after the treatment of macrophage
LPS-conditioned medium.
Finally, BrCa1 name (Breast Cancer-1) cannot be forgotten.
Examination of adipose tissue biology may provide important
insight into mechanistic links for the observed association between
higher body fat and the risk of several types of cancer, in particular
breast cancer [44].
In conclusion, the findings reported here are compatible with
the notion that chronic subclinical inflammation of obesity and
insulin resistance down-regulates the lipogenic pathway in
humans. BrCa1 might be involved in this process during periods
of long-lasting energy excess. Otherwise, BrCa1 down-regulation in
pre-adipocytes seems to be necessary in order to allow adipogen-
esis.
Methods
In vivo studies
Subjects and samples. 88 omental (OM) and 96 subcuta-
neous (SC) adipose tissue samples (51-paired fat samples) were
obtained from the lower abdominal wall/inguinal region of both
human fat depots during elective surgical procedures (cholecys-
tectomy, surgery of abdominal hernia and gastric by-pass surgery).
During surgery, biopsies of adipose tissues were obtained after an
overnight fast, washed in chilled 9 g/L NaCl solution, partitioned
into pieces, and immediately frozen in liquid nitrogen and stored
at 280uC until protein extraction. The surgeon aimed to obtain
the samples from similar anatomical locations in all the subjects.
These fat samples were provided from a whole cohort of 133
subjects (50 men and 83 women) with a body mass index (BMI)
between 20 and 70 kg/m2 who were invited to participate at the
Endocrinology Service of the Hospital Universitari de Girona Dr. Josep
Trueta (Girona, Spain), the Clinica Universitaria de Navarra (Navarra,
Spain), and the Hospital Carlos Haya de Ma´laga (Ma´laga, Spain).
Total and phosphorylated (P-) acetyl-CoA carboxylase (ACC)
levels were measured by ELISA in adipose tissue from 33
individuals (6 non-obese and 27 obese subjects). Total BrCa1
protein and phosphorylated (P-) BrCa1 were also analyzed in 11
subjects (6 obese and 5 non-obese) by western-blot.
All subjects were of Caucasian origin and reported that their
body weight had been stable for at least three months before the
study. They had no systemic disease and all were free of any
infections within the previous month before the study. Liver
disease and thyroid dysfunction were specifically excluded by
biochemical work-up. Other exclusion criteria for those patients
included the following: 1) clinically significant hepatic, neurolog-
ical, or other major systemic disease, including malignancy; 2)
history of drug or alcohol abuse, defined as .80 g/day, or serum
transaminase activity more than twice the upper normal range
limit; 3) elevated serum creatinine concentrations; 4) acute major
cardiovascular event in the previous 6 months; 5) acute illnesses
and current evidence of chronic inflammatory or infectious
diseases; and 6) mental illness rendering the subjects unable to
understand the nature, scope, and possible consequences of the
study. All subjects gave written informed consent after the purpose
of the study was explained to them. The experimental protocol
was approved by the Ethics Committee of all participant
institutions, including the Hospital Universitari de Girona Dr. Josep
Trueta (Girona, Spain), the Clinica Universitaria de Navarra (Navarra,
Spain), and the Hospital Carlos Haya de Ma´laga (Ma´laga, Spain),
respectively, so we certify that all applicable institutional regula-
tions concerning the ethical use of information and samples from
human volunteers were followed during this research.
Anthropometric and analytical measurements. BMI was
calculated as weight (in kilograms) divided by height (in meters)
squared. Deurenberg’s formula was used to estimate body fat
composition in those subjects [45]. The serum glucose levels were
measured in duplicate by the glucose oxidase method with a
Beckman Glucose Analyzer 2 (Brea, CA). The coefficient of variation
(CV) was 1.9%. Total serum cholesterol was measured through
the reaction of cholesterol esterase/oxidase/peroxidase, using a
BM/Hitachi 747. Low-density (LDL) and high-density (HDL)
cholesterol were quantified after precipitation with polyethylene
glycol at room temperature. Total serum triglycerides were
measured through the reaction of glycerol-phosphate-oxidase
and peroxidase, as previously described [46]. Whole blood
hemoglobin levels (EDTA sample, Coulter Electronics, Hialeah, FL)
were determined by routine laboratory tests.
Experimental procedures
Cell isolation. Approximately 5 g of both subcutaneous (SC)
and omental (OM) adipose tissue samples obtained during the
surgical procedures carried out in 12 subjects were aseptically
isolated and all visible connective tissue was removed. Tissues were
finely minced and subjected to a 1 h digestion at 37uC in a shaking
water bath. The digestion buffer included 100 mM HEPES (Sigma
Aldrich) buffer containing 120 mM NaCl, 50 mM KCl, 5 mM D-
glucose, 1 mM CaCl2, 1.5% type-V BSA, 2% penicillin/
streptomycin (P/S) and 0.15% collagenase Type I solution (Sigma
Aldrich). The collagenase Type I solution used to isolate stromal-
vascular cells (SVCs) and mature adipocytes (MAs) from fat
samples contained approximately 1.5 mg collagenase Type I/mL
(CLS type 1, Worthing Biochemical Corp). The remaining procedure
was similar to the previously described method for isolating SVCs
from adipose tissue [47]. Briefly, upon disintegration of the
adipose tissue aggregates, digested tissue was centrifuged and two
cellular fractions, a pellet of SVCs and a supernatant of MAs, were
placed in 20 ml of PBS 2% P/S and passed through sterile nylon
mesh filters (autoclaved metal screen, BD Biosciences) to isolate
digested cells. Finally, both SVCs (n= 12) and MAs (n= 12)
filtered fractions were washed and centrifuged for 5 min at 400 g
before be stored at 280uC. All these subjects were obese women
(BMI$30 kg/m2).
Cell culture. Commercially available cryo-preserved human
subcutaneous pre-adipocytes from one male subject with age $40
and BMI#25 (SP-F-1; Zen-Bio, Inc.) were placed on T-75 cell
culture flasks and cultured at 37uC and 5% CO2 in Dulbecco’s
modified Eagle’s medium (DMEM)/Nutrient Mix F-12 medium
(1:1, v/v) supplemented with Fetal Bovine Serum (FBS) 10%,
HEPES 1%, glutamine 1% and Penicillin/Streptomycin at 10 U/
mL (all from GIBCO, BRL; Grand Island, NY). One week later,
human SC pre-adipocytes were resuspended and cultured
(,40.000 cells/cm2, 3rd passage) in 6-well plates with Pre-
adipocyte Medium (PM; Zen-Bio, Inc.) composed of DMEM/
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Nutrient Mix F-12 medium (1:1, v/v), FBS 10%, HEPES 1%,
glutamine 1% and P/S 1% in a humidified 37uC incubator with
5% CO2. Twenty-four hours after plating, cells were checked for
complete confluence (day 0) and differentiation was induced using
Differentiation Medium (DM; Zen-Bio, Inc.), composed of PM with
human insulin, dexamethasone, isobutylmethyl-xanthine and
PPARc agonists (Rosiglitazone). After 7 days (day 7), DM was
replaced with fresh Adipocyte Medium (AM; Zen-Bio Inc.),
composed of DMEM/Nutrient Mix F-12 medium (1:1, v/v),
FBS, HEPES, biotin, panthothenate, insulin, dexamethasone,
penicillin, streptomycin and amphotericin, according to manufac-
turers’ guidelines. Two weeks after the initiation of differentiation
(day 14), cells appeared rounded with large lipid droplets apparent
in the cytoplasm. Cells were then considered mature adipocytes
(MAs), harvested and stored at 280uC for RNA and protein
extraction to study gene expression and protein levels.
Murine 3T3-L1 fibroblasts (CCL 92.1, American Type Culture
Collection) were grown to confluence at 37uC in 6-well plates in
DMEM with no added biotin or pantothenate, containing 10%
calf serum in incubators equilibrated with 10% CO2. Two days
post-confluence (day 0) differentiation was induced with, isobu-
tylmethyl-xanthine (0.5 mM), dexamethasone (0.25 mM) and
Insulin (1 pg/ml) in DMEM containing 10% fetal bovine serum.
After 2 days, isobutylmethyl-xanthine and dexamethasone were
removed and Insulin was maintained for 2 additional days. On
day 4, and thereafter, DMEM (without insulin supplementation)
plus 10% FBS was replaced every 2 days. On days 0, 7 and 14
before starting differentiation protocol, four replications of cells
were collected separately for total protein extraction. Cell samples
were washed in ice-cold PBS followed by homogenization assay
using RIPA lysis buffer (Upstate) supplemented with a protease
inhibitor cocktail (Sigma Aldrich) at 4uC for 30 min. Cellular debris
were eliminated by centrifugation of the diluted samples at
10,000 g for 10 min (4uC). Protein concentration was then
determined using Lowry assay.
Effects of macrophage-conditioned medium (MCM) on
BrCa1 expression. In vitro cultured mature adipocytes (14th day
post-differentiation) were further incubated (additional 48 h) with
fresh media (control), or with fresh media containing MCM
medium (25%), obtained from differentiated human monocyte cell
lines (THP-1; American Type Culture Collection) treated with medium
stimulated with 10 ng/ml LPS (Sigma Chemical) for 24 h, as
previously described [35]. After 48 h, mature adipocytes were
isolated, harvested and stored at 280uC for RNA extraction.
Gene expression analyses
RNA was prepared from both adipose tissue and human cellular
debris using RNeasy Lipid Tissue Mini Kit (QIAgen; Gaithersburg,
MD). The integrity of each RNA sample was checked by either
agarose gel electrophoresis or with an Agilent BioanalyzerH (Agilent
Technologies; Palo Alto, CA). Total RNA was quantified by means of
a spectrophotometer (GeneQuant, GE Health Care; Piscataway, NJ) or
with the BioanalyzerH and 3 mg of RNA was then reverse
transcribed to cDNA using High Capacity cDNA Archive Kit
(Applied Biosystems; Darmstadt, Germany) according to the manufac-
turer’s protocol.
Gene expression was assessed by real time PCR using the
LightCyclerH 480 Real-Time PCR System (Roche Diagnostics;
Barcelona, Spain), using TaqManH technology suitable for relative
gene expression quantification. The reaction was performed
following manufacturers’ protocol in a final volume of 7 ml. The
cycle program consisted of an initial denaturing of 10 min at 95uC
then 45 cycles of 15 sec denaturizing phase at 92uC and 1 min
annealing and extension phase at 60uC. Replicates and positive
and negative controls were included in all the reactions.
The commercially available and pre-validated TaqManH
primer/probe sets used were as follows: breast cancer 1 early
onset (BrCa1; Hs00173233_m1), sterol regulatory element binding
transcription factor 1 (SREBF1; Hs00231674_m1), fatty acid
synthase (FASN; Hs00188012_m1), and acetyl-coenzyme A car-
boxylase alpha (ACACA; Hs00167385_m1). Cyclophilin A (PPIA;
Hs99999904_m1) and ribosomic 18S (18S; Hs99999901_s1) were
analyzed and tested as endogenous control in each reaction. The
Second Derivative Maximum Method was used for the determi-
nation of the crossing points (Cp). A Cp value was obtained for
each amplification curve and DCp value was first calculated by
subtracting the Cp value for each endogenous control from the Cp
value for each sample and transcript. Fold changes were then
determined by calculating 22DCp. Findings normalizing by either
PPIA or 18S as endogenous control were correlated (r = 0.65,
p,1025; data not shown). Gene expression results are shown in all
cases in arbitrary units (AU) as expression ratio relative to PPIA
according to manufacturers’ guidelines.
Immunoblotting
For protein detection in Western blot, fat tissue and cellular
debris were homogenized in radioimmnuno precipitation assay
(RIPA) buffer (0.1% SDS, 0.5% sodium deoxycholate, 1%
Nonidet P-40, 150 mM NaCl, 50 mM Tris-HCl, pH 8.0),
supplemented with protease inhibitors (1 mM phenylmethylsulfo-
nyl fluoride, 2 g/ml aprotinin and 2 g/ml leupeptin). Cellular
debris and lipids were eliminated by centrifugation of the
solubilized samples at 13,000 rpm for 30 minutes, recovering the
soluble fraction below the fat supernatant and avoiding the un-
homogenized material at the bottom of the centrifuge tube.
Protein concentration was determined by BCA Protein Assay
(Pierce; Rockford, IL, USA). RIPA protein extracts (ca. 10 mg) were
loaded and resolved on 7–14% SDS-PAGE and transferred to
Hybond ECL nitrocellulose membranes by conventional proce-
dures. Membranes were stained with 0.15% Ponceau red (Sigma-
Aldrich; St Louis, MO, USA) to ensure equal loading after transfer
and then blocked with 5% (w/v) BSA or dried nonfat milk in TBS
buffer with 0.1% Tween 20. The antibodies used for WB analysis
revealed in each case single bands at the expected molecular
masses. The primary antibodies used were: from Cell Signaling
rabbit anti-phospho-BrCa1 (Ser1524); from Santa Cruz Biotechnology
rabbit anti-BrCa1 and goat anti-Beta-Actin; and from Ambion
mouse anti-GAPDH. Blots were incubated with the appropriate
IgG-HRP-conjugated secondary antibody. Immunoreactive bands
were visualized with ECL-plus reagent kit (GE Healthcare). Blots
were exposed for different times; exposures in the linear range of
signal were selected for densitometric evaluation. Optical densities
of the immunoreactive bands were measured using Scion ImageH
software. Final results are expressed as ratio relative to b-actin for
each fat sample or GADPH in 3T3-L1. Statistical comparisons of
the densitometry data were carried out using the Student’s t test,
and results were expressed as means 6 standard deviation (SD)
using SPSS 16.0 (SPSS Inc., Illinois, USA). Statistical significance
was set at P,0.05.
ELISA
Total acetyl-CoA carboxylase 1 (ACC) and ACC phosphory-
lated at Serine residue 79 (P-ACC) were measured by enzyme
linked immunoassay (ELISA) kit (Invitrogen Ltd; Paisley, UK) in
lysates of human adipose tissue and cellular debris homogenized
by RIPA lysis buffer as previously described (see above). Results
from the assay intended for the detection of total ACC
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independently of phosphorylation status were used for normaliza-
tion of phosphorylated ACC [pS79]. The analytical sensitivity of
these assay were ,0.05 ng/mL of ACC total and ,0.5 Units/mL
of phosphorylated ACC [pS79]. The intra- and inte-rassay CV
were, respectively, 3.3% and 6.1% for ACC total, and 4.6% and
5.8% for P-ACC [pS79].
Statistical analyses
Descriptive results of continuous variables are expressed as
mean 6SD. Before statistical analysis, normal distribution and
homogeneity of the variances were evaluated using Levene’s test.
One factor ANOVA and Student’s t test were used to compare
variables according groups. Levels of statistical significance were
set at P,0.05. The relationships between quantitative variables
were tested using Pearson’s correlation coefficient. The statistical
analyses and graphics were performed using the program SPSS
(v13.0; SPSS Inc., Illinois, USA).
Supporting Information
Figure S1 Comparisons between fat depots. Mean and
95% confidence interval for the mean of gene expression levels for
BrCa1 (Fig. S1a), FASN (Fig. S1c), ACC (Fig. S1d), and SREBP-1c (Fig.
S1d), and mean 62.0 SE for phosphorylated ACC normalized
versus ACC total (ratio P-ACC/ACC) in omental (OM) and
subcutaneous (SC) adipose tissue (n = 51 paired samples; Fig. S1b).
* p,0.05 for comparisons between fat depots.
(TIF)
Figure S2 BrCa1 in adipocytes and stromal-vascular
cells. Mean and 95% confidence interval for the mean of gene
expression levels for BrCa1 (Fig. S2a), FASN (Fig. S2b), ACC (Fig.
S2c), and SREBP-1c (Fig. S2d), in stromal-vascular cells (SVCs) and
mature adipocytes (MAs) isolated from adipose tissue biopsies
(n = 12 paired samples). * p,0.0001 for comparisons between ex
vivo isolated cells.
(TIF)
Acknowledgments
We greatly appreciate the technical assistance of Gerard Pardo, Oscar
Rovira, and Roser Rodriguez (Unit of Diabetes, Endocrinology and Nutrition
(UDEN), Institut d’Investigacio´ Biome`dica de Girona (IdIBGi), Hospital Universitari
de Girona Dr. Josep Trueta; Girona, Spain). The work of all the members of the
multidisciplinary obesity team of the Clı´nica Universitaria de Navarra is also
gratefully acknowledged.
Author Contributions
Conceived and designed the experiments: FJO JMF-R. Performed the
experiments: FJO JMMDM EG-S MG-S. Analyzed the data: FJO JMF-R.
Contributed reagents/materials/analysis tools: WR FJT GF BP. Wrote the
paper: FJO JMF-R. Obtained the biopsies, the anthropometrical
characteristics, and the written consent of patients: JIR-H BR. Participated
in the conception and the coordination of the study: WR FJT GF BP.
References
1. Mobbs CV, Makimura H (2002) Block the FAS, lose the fat. Nat Med 8:
335–336.
2. Wakil SJ, Stoops JK, Joshi VC (1983) Fatty acid synthesis and its regulation.
Annu Rev Biochem 52: 537–579.
3. Brownsey RW, Boone AN, Elliott JE, Kulpa JE, Lee WM (2006) Regulation of
acetyl-CoA carboxylase. Biochem Soc Trans 34: 223–227.
4. Mayas MD, Ortega FJ, Gomez-Huelgas R, Roca N, Fernandez-Real JM, et al.
(2009) Decrease in FASN expression in adipose tissue of hypertensive
individuals. Am J Hypertens 22: 1258–1262.
5. Minehira K, Vega N, Vidal H, Acheson K, Tappy L (2004) Effect of
carbohydrate overfeeding on whole body macronutrient metabolism and
expression of lipogenic enzymes in adipose tissue of lean and overweight
humans. Int J Obes Relat Metab Disord 28: 1291–1298.
6. Ortega FJ, Mayas D, Moreno-Navarrete JM, Catalan V, Gomez-Ambrosi J, et
al. (2010) The gene expression of the main lipogenic enzymes is downregulated
in visceral adipose tissue of obese subjects. Obesity (Silver Spring) 18: 13–20.
7. Ortega FJ, Vazquez-Martin A, Moreno-Navarrete JM, Bassols J, Rodriguez-
Hermosa J, et al. (2009) Thyroid hormone responsive Spot 14 increases during
differentiation of human adipocytes and its expression is down-regulated in
obese subjects. Int J Obes (Lond).
8. Ranganathan G, Unal R, Pokrovskaya I, Yao-Borengasser A, Phanavanh B, et
al. (2006) The lipogenic enzymes DGAT1, FAS, and LPL in adipose tissue:
effects of obesity, insulin resistance, and TZD treatment. J Lipid Res 47:
2444–2450.
9. Brook CG, Lloyd JK, Wolf OH (1972) Relation between age of onset of obesity
and size and number of adipose cells. Br Med J 2: 25–27.
10. Knittle JL, Timmers K, Ginsberg-Fellner F, Brown RE, Katz DP (1979) The
growth of adipose tissue in children and adolescents. Cross-sectional and
longitudinal studies of adipose cell number and size. J Clin Invest 63: 239–246.
11. Roncari DA, Lau DC, Kindler S (1981) Exaggerated replication in culture of
adipocyte precursors from massively obese persons. Metabolism 30: 425–427.
12. Avram MM, Avram AS, James WD (2007) Subcutaneous fat in normal and
diseased states 3. Adipogenesis: from stem cell to fat cell. J Am Acad Dermatol
56: 472–492.
13. Hausman DB, DiGirolamo M, Bartness TJ, Hausman GJ, Martin RJ (2001)
The biology of white adipocyte proliferation. Obes Rev 2: 239–254.
14. Fajas L (2003) Adipogenesis: a cross-talk between cell proliferation and cell
differentiation. Ann Med 35: 79–85.
15. Nishimura S, Manabe I, Nagasaki M, Hosoya Y, Yamashita H, et al. (2007)
Adipogenesis in obesity requires close interplay between differentiating
adipocytes, stromal cells, and blood vessels. Diabetes 56: 1517–1526.
16. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444:
860–867.
17. Ferre P, Foufelle F (2007) SREBP-1c transcription factor and lipid homeostasis:
clinical perspective. Horm Res 68: 72–82.
18. Nathanson KL, Wooster R, Weber BL (2001) Breast cancer genetics: what we
know and what we need. Nat Med 7: 552–556.
19. Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, et al. (2007)
Abraxas and RAP80 form a BRCA1 protein complex required for the DNA
damage response. Science 316: 1194–1198.
20. Bernard-Gallon DJ, De Latour MP, Sylvain V, Vissac C, Aunoble B, et al.
(2001) Brca1 and Brca2 protein expression patterns in different tissues of murine
origin. Int J Oncol 18: 271–280.
21. Lane TF, Deng C, Elson A, Lyu MS, Kozak CA, et al. (1995) Expression of
Brca1 is associated with terminal differentiation of ectodermally and
mesodermally derived tissues in mice. Genes Dev 9: 2712–2722.
22. Marquis ST, Rajan JV, Wynshaw-Boris A, Xu J, Yin GY, et al. (1995) The
developmental pattern of Brca1 expression implies a role in differentiation of the
breast and other tissues. Nat Genet 11: 17–26.
23. Gowen LC, Johnson BL, Latour AM, Sulik KK, Koller BH (1996) Brca1
deficiency results in early embryonic lethality characterized by neuroepithelial
abnormalities. Nat Genet 12: 191–194.
24. Hakem R, de la Pompa JL, Sirard C, Mo R, Woo M, et al. (1996) The tumor
suppressor gene Brca1 is required for embryonic cellular proliferation in the
mouse. Cell 85: 1009–1023.
25. Liu CY, Flesken-Nikitin A, Li S, Zeng Y, Lee WH (1996) Inactivation of the
mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in
early postimplantation development. Genes Dev 10: 1835–1843.
26. Magnard C, Bachelier R, Vincent A, Jaquinod M, Kieffer S, et al. (2002)
BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT
domains. Oncogene 21: 6729–6739.
27. Ray H, Moreau K, Dizin E, Callebaut I, Venezia ND (2006) ACCA
phosphopeptide recognition by the BRCT repeats of BRCA1. J Mol Biol 359:
973–982.
28. Ray H, Suau F, Vincent A, Dalla Venezia N (2009) Cell cycle regulation of the
BRCA1/acetyl-CoA-carboxylase complex. Biochem Biophys Res Commun
378: 615–619.
29. Brunet J, Vazquez-Martin A, Colomer R, Grana-Suarez B, Martin-Castillo B, et
al. (2008) BRCA1 and acetyl-CoA carboxylase: the metabolic syndrome of
breast cancer. Mol Carcinog 47: 157–163.
30. Moreau K, Dizin E, Ray H, Luquain C, Lefai E, et al. (2006) BRCA1 affects
lipid synthesis through its interaction with acetyl-CoA carboxylase. J Biol Chem
281: 3172–3181.
31. Shen Y, Tong L (2008) Structural evidence for direct interactions between the
BRCT domains of human BRCA1 and a phospho-peptide from human ACC1.
Biochemistry 47: 5767–5773.
32. McLaughlin T, Sherman A, Tsao P, Gonzalez O, Yee G, et al. (2007) Enhanced
proportion of small adipose cells in insulin-resistant vs insulin-sensitive obese
individuals implicates impaired adipogenesis. Diabetologia 50: 1707–1715.
BrCa1, Lipo/adipogenesis and Adiposity
PLoS ONE | www.plosone.org 8 May 2012 | Volume 7 | Issue 5 | e33233
33. Goossens GH (2008) The role of adipose tissue dysfunction in the pathogenesis
of obesity-related insulin resistance. Physiol Behav 94: 206–218.
34. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, et al. (2007) Metabolic
endotoxemia initiates obesity and insulin resistance. Diabetes 56: 1761–1772.
35. Moreno-Navarrete JM, Ortega FJ, Ricart W, Fernandez-Real JM (2009)
Lactoferrin increases (172Thr)AMPK phosphorylation and insulin-induced
(p473Ser)AKT while impairing adipocyte differentiation. Int J Obes (Lond)
33: 991–1000.
36. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, et al. (2002) Absence of
sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers
but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice. J Biol Chem 277:
19353–19357.
37. Sekiya M, Yahagi N, Matsuzaka T, Takeuchi Y, Nakagawa Y, et al. (2007)
SREBP-1-independent regulation of lipogenic gene expression in adipocytes.
J Lipid Res 48: 1581–1591.
38. Blackshear PE, Goldsworthy SM, Foley JF, McAllister KA, Bennett LM, et al.
(1998) Brca1 and Brca2 expression patterns in mitotic and meiotic cells of mice.
Oncogene 16: 61–68.
39. Xu X, Wagner KU, Larson D, Weaver Z, Li C, et al. (1999) Conditional
mutation of Brca1 in mammary epithelial cells results in blunted ductal
morphogenesis and tumour formation. Nat Genet 22: 37–43.
40. Swierczynski J, Zabrocka L, Goyke E, Raczynska S, Adamonis W, et al. (2003)
Enhanced glycerol 3-phosphate dehydrogenase activity in adipose tissue of obese
humans. Mol Cell Biochem 254: 55–59.
41. Miettinen TA, Tilvis RS (1981) Cholesterol synthesis and storage in adipose
tissue. Int J Obes 5: 613–618.
42. Smith J, Al-Amri M, Dorairaj P, Sniderman A (2006) The adipocyte life cycle
hypothesis. Clin Sci (Lond) 110: 1–9.
43. Bae I, Fan S, Meng Q, Rih JK, Kim HJ, et al. (2004) BRCA1 induces
antioxidant gene expression and resistance to oxidative stress. Cancer Res 64:
7893–7909.
44. Hjartaker A, Langseth H, Weiderpass E (2008) Obesity and diabetes epidemics:
cancer repercussions. Adv Exp Med Biol 630: 72–93.
45. Deurenberg P, van der Kooy K, Leenen R, Weststrate JA, Seidell JC (1991) Sex
and age specific prediction formulas for estimating body composition from
bioelectrical impedance: a cross-validation study. Int J Obes 15: 17–25.
46. Fernandez-Real JM, Broch M, Ricart W, Casamitjana R, Gutierrez C, et al.
(1998) Plasma levels of the soluble fraction of tumor necrosis factor receptor 2
and insulin resistance. Diabetes 47: 1757–1762.
47. Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C (2008) Adipose-derived
stem cells: isolation, expansion and differentiation. Methods 45: 115–120.
BrCa1, Lipo/adipogenesis and Adiposity
PLoS ONE | www.plosone.org 9 May 2012 | Volume 7 | Issue 5 | e33233
